Bioheart, Inc. (Nasdaq: BHRT), a pioneer in the biotechnology field with their “myoblast” muscle stem cell therapy for heart failure patients, recently announced that the company has received a Notice of Allowance from the US Patent and Trademark Office for nine new patents. The patents cover the use of electrical stimulation to enhance stem cell regeneration of damaged heart muscle. The combination of revolutionary patent approvals and myoblast stem cell therapy could help BHRT become a market force.

These patent approvals are a milestone moment for BHRT. The patents harness the natural electro-chemical instructional program that teaches stem cells to turn into heart muscle. So, after a heart failure patient undergoes the myoblast stem cell injection, the very muscle stem cells injected are then taught to become heart muscle. The patent also covers preconditioning stem cells to become heart muscle during the culturing process before they are injected. The myoblast therapy and patents have the ability to not only save lives, but position BHRT as a major market player.

The patents and their tremendous benefits have been lauded by leading industry experts, notably David Holmes, M.D., the Chairman of Cardiology for the Mayo Clinic in Rochester, MN, who commented on the announcement, “This truly has the potential to be a landmark invention in the field of heart failure treatment.”

BHRT has developed proprietary processes that have the potential to revolutionize the health care industry, save lives, and make BHRT the leader in heart failure treatment. This all translates into a formula for growth.

Link to video of Bioheart presentation conducted by Howard Leonhardt, CEO.
 

Safe Harbor Statement
This announcement contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the company’s ability to obtain the necessary financing to continue and expand operations, to market its products in new markets and to offer products at competitive pricing, to attract and retain management, and to integrate and maintain technical information and management information systems; compliance with laws and regulations of the PRC, the effects of currency policies and fluctuations, general economic conditions and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.